John H Stewart

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6517110/publications.pdf

Version: 2024-02-01

933264 794469 22 950 10 19 citations g-index h-index papers 23 23 23 1278 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer. Journal of Surgical Research, 2020, 245, 127-135.	0.8	11
2	Outcomes of Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients Older than 70 Years; Survival Benefit at Considerable Morbidity and Mortality: A Reply. Annals of Surgical Oncology, 2017, 24, 602-602.	0.7	5
3	Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Gallbladder Cancer: A Retrospective Review. American Surgeon, 2014, 80, 710-713.	0.4	10
4	Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreaticÂadenocarcinoma. Journal of Surgical Research, 2014, 187, 412-426.	0.8	20
5	Asa G Yancey: A Quiet Giant in American Surgery. Journal of the American College of Surgeons, 2014, 219, 842-845.	0.2	3
6	Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Experience with 1,000 Patients. Journal of the American College of Surgeons, 2014, 218, 573-585.	0.2	221
7	Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): Overview of 481 cases Journal of Clinical Oncology, 2014, 32, 565-565.	0.8	O
8	Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus. Surgery, 2013, 153, 333-343.	1.0	24
9	Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors. Surgery, 2013, 154, 1323-1330.	1.0	8
10	Transcriptional Targeting of Bone Morphogenetic Protein Receptors: Is it Ready for Prime Time?. Journal of Surgical Research, 2012, 178, 601-603.	0.8	0
11	Long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy compared with hepatic resection for metastatic colorectal cancer Journal of Clinical Oncology, 2012, 30, 630-630.	0.8	2
12	Geographic and socioeconomic determinants of participation by elderly patients in surgical oncology trials Journal of Clinical Oncology, 2012, 30, 6127-6127.	0.8	0
13	Role of bacillus Calmette–Guérin in the treatment of advanced melanoma. Expert Review of Anticancer Therapy, 2011, 11, 1671-1676.	1.1	44
14	Intraoperative Imprint Cytology for Evaluation of Sentinel Lymph Nodes from Merkel Cell Carcinoma. American Surgeon, 2009, 75, 615-619.	0.4	6
15	The Current Role of Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Dissemination of Appendiceal Tumors. Current Problems in Cancer, 2009, 33, 142-153.	1.0	4
16	Translation Considerations for Hyperthermic Intraperitoneal Chemotherapy. Current Problems in Cancer, 2009, 33, 194-202.	1.0	1
17	A Phase I Trial of Oxaliplatin for Intraperitoneal Hyperthermic Chemoperfusion for the Treatment of Peritoneal Surface Dissemination from Colorectal and Appendiceal Cancers. Annals of Surgical Oncology, 2008, 15, 2137-2145.	0.7	66
18	Intraperitoneal hyperthermic chemotherapy: an evolving paradigm for the treatment of peritoneal surface malignancies. Expert Review of Anticancer Therapy, 2008, 8, 1809-1818.	1.1	17

#	Article	IF	CITATION
19	The Essential Role of the Mitochondria and Reactive Oxygen Species in Cisplatin-Mediated Enhancement of Fas Ligand-Induced Apoptosis in Malignant Pleural Mesothelioma. Journal of Surgical Research, 2007, 141, 120-131.	0.8	24
20	Participation in Surgical Oncology Clinical Trials: Gender-, Race/Ethnicity-, and Age-based Disparities. Annals of Surgical Oncology, 2007, 14, 3328-3334.	0.7	212
21	Appendiceal Neoplasms With Peritoneal Dissemination: Outcomes After Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy. Annals of Surgical Oncology, 2006, 13, 624-634.	0.7	147
22	Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Current Status and Future Directions. Annals of Surgical Oncology, 2005, 12, 765-777.	0.7	125